Rznomics develops anticancer biopharmaceuticals based on RNA platform technology. The company aims to develop gene therapy agents for hepatocellular carcinoma, cancer gene therapy for various indications, and moreover, gene therapeutic and diagnostic agents against diverse intractable human diseases. Rznomics was founded in 2017 and is based in Yongin-si, South Korea.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.